HIGHBuilt-in & outside partyPipeline
STRO-004
“10-K Item 1: 'Our highest priority wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor'”
STRO · Concentration risk · 10-K extracted
Sutro Biopharma (STRO) concentration risks
Updated
The most significant concentration Sutro Biopharma discloses is STRO-004, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Sutro Biopharma’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Sutro Biopharma's concentration profile reflects the reality of a clinical-stage biotech: its highest priority wholly-owned product candidate is STRO-004, a single homogeneous antibody-drug conjugate directed against tissue factor. This is a structural characteristic of the pipeline rather than a customer or supplier dependency — the company's near-term value creation is tied heavily to the clinical progress of this one lead program, and its character is described as mixed, meaning both the scale of the opportunity and the risk of concentration in a single candidate cut in different directions for how the exposure ultimately plays out. With no other concentration items disclosed in the available sources — no customer, geographic, or supplier claims to weigh alongside it — STRO-004's progress is effectively the dominant variable in Sutro's near-term trajectory. A positive clinical readout or regulatory milestone for this lead candidate could disproportionately move the investment thesis, just as a setback would. For investors, this means the stock's risk and reward are less about diversified commercial execution and more about the binary, idiosyncratic outcomes tied to a single pipeline asset advancing through development.
For the engine’s reasoning on STRO’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| STRO● | Sutro Biopharma, Inc. | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.